Out-of-pocket costs drove abandonment: fill rates fell from ~80% at ≤$15 to ~30% at $500–$2000, and to 21.6% when >$2000 commercially. Prior authorization dominated rejection reasons (32.1% Medicare; ...
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175. Most new prescriptions for specialty oral anticancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results